絞り込み

16766

広告

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

著者 Agalliu I , Ortega RA , Luciano MS , Mirelman A , Pont-Sunyer C , Brockmann K , Vilas D , Tolosa E , Berg D , Warø B , Glickman A , Raymond D , Inzelberg R , Ruiz-Martinez J , Mondragon E , Friedman E , Hassin-Baer S , Alcalay RN , Mejia-Santana H , Aasly
Mov Disord.2019 Jul 26 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (11view , 1users)

Full Text Sources

Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls.
PMID: 31348549 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード